GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A ProblemSeeking Alpha • 08/14/23
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023Business Wire • 08/02/23
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023Business Wire • 07/19/23
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid LeukemiaBusiness Wire • 06/15/23
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare ConferenceBusiness Wire • 05/31/23
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023Business Wire • 05/03/23
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022Business Wire • 03/29/23
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023Business Wire • 03/16/23
GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care ConferenceBusiness Wire • 03/01/23
GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring CommitteeBusiness Wire • 02/15/23
GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual MeetingBusiness Wire • 12/12/22
Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 12/02/22